MaaT Pharma SA (id:10894 MAAT)
7.86 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/28/2024 3:38:18 AM)
Exchange closed, opens in 5 hours 21 minutes
-0.25 EUR (-0.25%)
-3.20 EUR (-3.20%)
7.97 EUR (7.97%)
-1.75 EUR (-1.75%)
10.70 EUR (10.70%)
-41.78 EUR (-41.78%)
About MaaT Pharma SA
Market Capitalization 114.46M
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
| Headquarters (address) |
70 Avenue Tony Garnier Lyon 69007 France |
| Phone | 33 4 28 29 14 00 |
| Website | https://www.maatpharma.com |
| Employees | 54 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | MAAT |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 6.30 - 9.90 |
| Market Capitalization | 114.46M |
| P/E forward | -3.20 |
| Price/Sale | 44.52 |
| Price/Book | 4.48 |
| Beta | 0.193 |
| EPS | -1.70 |
| EPS France (ID:70, base:331) | 3.06 |